Company profile
PB&B SA
PB&B’s novel injectable technology allows plastic surgeons and dermatologists to enhance fat tissue volume with lipids to naturally remodel facial and body areas. Patent granted to date in 13 countries (USA, China, etc.) with all claims and applications. Full FTO (Freedom-to-Operate). • Developed by an international team of plastic surgeons and bioengineers. Technology entering clinical testing phase towards an approval in Europe, US, and China in 2025. • PB&B has won numerous innovation and startup awards, including the IMCAS Innovation of the Year award 2018 (largest global medical aesthetics congress – Paris, France). • 3 Innovation government grants (CH, EU, CN) approved based on innovation & market potential. • PB&B Funding to date: $7 Million.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
